endpts.com·Jun 1, 2026
Turn Therapeutics has reported promising Phase 2 data for its topical treatment for eczema, showing that patients experienced symptom improvement more rapidly than usual, contributing to a rise in overall biopharma sentiment.
The content highlights that Turn Therapeutics' eczema drug has shown rapid symptom improvement in Phase 2 trial data, indicating a potential breakthrough in atopic dermatitis treatment. For a professional in healthtech and biotech, this suggests a promising investment opportunity or partnership potential, especially as the biopharma sentiment rises, signaling renewed investor interest and confidence in the sector.